Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 8/20 | 1.00 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.86 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.79 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.79 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.79 |
| ▸ | TLK1 | Q9UKI8 | 3/20 | 0.79 |
| ▸ | FLT1 | P17948 | 3/20 | 0.79 |
| ▸ | PLK4 | O00444 | 3/20 | 0.79 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.79 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.79 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.79 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.79 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.79 |
| ▸ | INSR | P06213 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830179 | 1.00 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29354429 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672513 | 0.93 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2115759 | 0.93 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL1673439 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL2116670 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL22649592 | 0.91 | PDGFRB (0.87) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29397832 | 0.90 | PDGFRB (0.95) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL22649596 | 0.90 | PDGFRB (0.86) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672543 | 0.89 | PDGFRB (0.83) | PDGFRBKDRFGFR1TLK2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | claimed |
| US-7119209-B2 | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050171357-A1 | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2005-08-04 | — | — | US | disclosed |
| EP-1476443-A2 | PROCESS FOR PREPARING INDOLINONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030229229-A1 | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-11 | — | — | US | disclosed |
| WO-2003070725-A2 | PROCESS FOR PREPARING INDOLINONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171357-A1 | Process for preparing indolinone derivatives | CYP2B6, CYP2D6, CYP3A4 | PDGFRB 1410/4885KDR 3047/4885FGFR1 1761/4885 |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | PDGFRB 3475/4885KDR 3687/4885FGFR1 1091/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | PDGFRB 123/4885KDR 71/4885FGFR1 48/4885 |
| US-20030229229-A1 | Process for preparing indolinone derivatives | CYP2B6, CYP2D6, CYP3A4 | PDGFRB 1410/4885KDR 3047/4885FGFR1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.